We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current VBIZF market cap is 183.72M. The company's latest EPS is CNY -0.0537 and P/E is -1.49.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 323.06M | 696.96M | 2.1B | 2.38B | 2.16B |
| Operating Income | 42.1M | 108.94M | 259.3M | 299.26M | 19.64M |
| Net Income | 265.87M | -386.88M | 287.55M | -528.48M | -116.11M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 1.9B | 8.15B | 8.04B | 7.92B | 7.45B |
| Total Liabilities | 121.39M | 4.4B | 4.13B | 4.32B | 3.76B |
| Total Equity | 1.78B | 3.76B | 3.91B | 3.6B | 3.69B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 46.01M | 32.17M | 77.83M | 386.05M | 383.41M |
| Investing | -290.06M | -3.84B | -868.84M | -372.8M | 439.17M |
| Financing | 984.86M | 5.31B | -653.16M | -143.2M | -429.5M |
| Market Cap | 183.72M |
| Price to Earnings Ratio | -1.49 |
| Price to Sales Ratio | 0.08 |
| Price to Cash Ratio | 0.17 |
| Price to Book Ratio | 0.05 |
| Dividend Yield | - |
| Shares Outstanding | 2.16B |
| Average Volume (1 week) | 1,000 |
| Average Volume (1 Month) | 3.34k |
| 52 Week Change | -52.91% |
| 52 Week High | 0.2319 |
| 52 Week Low | 0.05 |
| Spread (Intraday) | 0.06 (55.08%) |
| Company Name | Viva Biotech Holdings (PK) |
| Address |
po box 309 grand cayman KY1-1104 |
| Website | https://www.vivabiotech.com |
| Industry | drugs and proprietary-whsl (5122) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
